Our History

Alector is rooted in an inspiration to make new connections and the conviction to challenge accepted norms. Learn more about how we got here.

2021

Presented 12-month results from AL001 Phase 2 clinical study in symptomatic FTD-GRN participants at Alzheimer’s Association International Congress

Presented data on AL002 program in Alzheimer’s disease at AAIC 2021

Forged collaborative agreement with GlaxoSmithKline to co-develop and co-commercialize progranulin franchise programs AL001 and AL101

Initiated INVOKE Phase 2 clinical trial of AL002 for treatment of patients with early Alzheimer’s disease

Commenced enrollment of AL001 INFRONT randomized Phase 3 clinical trial for treatment of patients with dementia with a progranulin gene mutation (FTD-GRN)

Shared initial data from Phase 1b and Phase 2 clinical studies of AL001 at Alzheimer’s Association International Congress

Published preclinical data for AL002 in the Journal of Experimental Medicines

Presented preclinical data from immun0-oncology product candidates AL008 being developed for treatment of cancers

Entered into collaborative licensing agreement with Innovent to develop and commercialize AL008 for oncology indications in China

Initiated Phase 1b clinical study of AL003 in Alzheimer’s disease

2020

2019

Initiated Phase 1 clinical trial of AL101 to increase progranulin levels in healthy volunteers

Granted Fast Track Designation for AL001 in frontotemporal dementia

Began INFRONT Phase 2 trial of AL001 for treatment of patients with frontotemporal dementia

Hired 100th employee

Announced data from INFRONT Phase 1b clinical trial of AL001 showing increases in progranulin levels to normal levels

Started INTERCEPT Phase 1 clinical trial of AL003, being developed for the treatment of patients with Alzheimer’s disease

Alector announces pricing of its initial public offering and starts trading on the Nasdaq

Began dosing in INVOKE Phase 1 trial of AL002 in healthy volunteers and participants with Alzheimer’s disease

Initiated Phase 1 clinical study of AL001 in healthy volunteers and participants with frontotemporal dementia that carry the GRN mutation

Received Orphan Drug designation from U.S. Food and Drug Administration for AL001 for the treatment of frontotemporal dementia

Closed $133M Series E crossover round financing with new and existing investors to advance immuno-neurology pipeline candidates into the clinic

Announced indications for first three therapeutic candidates: AL001 for frontotemporal dementia, AL002 for Alzheimer’s disease and AL003 for Alzheimer’s disease

2018

2017

Formed partnership with AbbVie to co-develop Alector’s Alzheimer’s-focused lead programs, AL002 and AL003

Added new investors through $29.5M Series D financing

Dementia Discovery Fund, an innovative global investment fund launched in October 2015, chooses Alector for first award

2016

2015

Raised $32M in Series C fund with investment from MRL Ventures, OrbiMed, Polaris, Google Ventures, Topspin Partners, and Mission Bay Capital, among others

Named one of 2015’s “Fierce 15” private companies by FierceBiotech

Disclosed research focus on immuno-neurology and discovery of 12 leads for new neurodegeneration treatments

Series B funding round closes with investments from Orbimed and Polaris Ventures

Disclosed generation of four novel antibody drugs against disease-altering targets and plan to read and took two forward in preclinical development

Signed collaborative research agreement with Johnson & Johnson Innovation Center to fund one target through proof-of-concept in disease models

Alector and Adimab announce strategic alliance to access antibody technologies

2014

2013

Co-founders Arnon Rosenthal, Ph.D., Tillman Gerngross, Asa Abeliovich, Ph.D., and Errik Anderson launch Alector with announcement of Series A financing from Orbimed and Polaris Ventures

Alector moves to life science incubator QB3

Alector is incorporated

Selected Alector as the company name to represent heroic ideals ubiquitous in Greek mythology

Close